HOME >> BIOLOGY >> NEWS
Therapy hinders AIDS virus from evolving drug resistance, Hopkins researchers find

A team of scientists from Johns Hopkins Children's Center and two other institutions have found that low levels of HIV-1 virus in the blood of children and adults undergoing a common combination drug therapy does not necessarily indicate the virus is becoming resistant to these life-prolonging medications.

In the first study to show a low level of viral activity in children using the therapy, called HAART (highly active anti-retroviral therapy), a team led by Children's Center infectious disease researcher Deborah Persaud, M.D., says that bloodstream signatures of HIV-1 revealed no genetic signs that the virus was developing resistance. The finding, published in this week's Journal of the American Medical Association, has implications for the design and future treatment strategies in fighting the onset of AIDS.

"Going into the study, we thought it was possible that even low levels of virus activity could result in the evolution of resistance to HAART drugs," Persaud says. "But both the children and adults in our study showed that the therapy is working."

The report also shows that occasional increases in apparent virus activity, called "blips," do not necessarily indicate the virus is resisting the protease inhibitors and anti-retroviral drugs that make up HAART.

From the blood samples of 20 study participants, all of whom had been on HAART at least 25 months, the research team looked for the unique genetic signature left by very low levels of HIV-1, a virus that inserts itself into the human genome and begins replicating as though it were any other set of human genes.

The researchers compared each viral genetic sequence to other viral sequences from the same patient, to other patients' viral sequences and to sequences that represent drug-resistant viruses. The researchers found that viral replication and mutation had remained suppressed by HAART. Two of the 20 study participants, who responded less than optimally to HAART
'"/>

Contact: David Bricker
dbricker@jhmi.edu
410-223-1728
Johns Hopkins Medical Institutions
10-Jul-2001


Page: 1 2

Related biology news :

1. 1st International Conference on Cell Therapy for Cardiovascular Disease
2. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
3. Braunschweig Prize 2003 for Molecular Cancer Therapy
4. Alliance for Cancer Gene Therapy announces $1.5 million in national grants to young investigators
5. New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy
6. Invitation To Cover: American Society Of Gene Therapy Meeting
7. Gene Therapy For Pain
8. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy
9. Shock Therapy Exceeds Expectations In Cleaning Up Contaminated Soils
10. Penn Researchers Develop Gene Therapy Technique That Reverses Muscle Membrane Weakness In Muscular Dystrophy Variant
11. University Of Pittsburgh Involved In First Successful Example Of Gene Therapy For Pain Control

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... FRANCISCO (PRWEB) , ... August 06, 2020 , ... ... life sciences industry, is pleased to announce that Eric Chen and Jessica Wong ... President of Product Management & Strategy, respectively. , Eric Chen heads development efforts ...
(Date:8/5/2020)... PENSACOLA, Fla. (PRWEB) , ... August 05, 2020 , ... ... to cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly ... a defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft ...
(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical ... this project is to develop, optimize, and scale-up a highly efficient mammalian cell ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... BEDFORD, Mass. (PRWEB) , ... July 29, 2020 ... ... of highly reliable, solid-state radar transmitter systems that can be configured to drive ... a single controller that can drive one or two switches in a push-pull ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and ... it did not take off as quickly as people initially expected, and where eSource ... capturing data electronically for clinical trials and then repurposing it for downstream analysis, at ...
(Date:7/22/2020)... (PRWEB) , ... July 22, 2020 , ... Join experts ... John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... the regulating body in China for drugs and medical devices. Specifically, for medical devices, ...
(Date:7/18/2020)... ... 16, 2020 , ... Medial EarlySign , a leader ... of high-burden diseases, and Centric Consulting, a business and technology consulting firm, today ... data in order to identify and prioritize patients for care. , Combining Centric’s ...
Breaking Biology Technology:
Cached News: